1. Introduction

Leasing of genetic materials for research refers to contractual arrangements under which biological materials containing genetic information are made available to researchers, universities, biotechnology companies, pharmaceutical firms, or laboratories for a defined research purpose and period, subject to agreed conditions.

Genetic materials may include:

DNA, RNA, genes, and genomic sequences.

Biological samples such as blood, tissue, saliva, and cells.

Cell lines, stem-cell lines, and cultured microorganisms.

Genetically modified organisms and research strains.

Plant genetic resources, seeds, and germplasm.

Biological samples containing associated genomic and health data.

The term leasing requires an important legal distinction. Genetic materials are not necessarily ordinary commercial property that can be leased like land or machinery. Depending on the jurisdiction and type of material, the transaction may legally be a material transfer agreement (MTA), research licence, bailment, deposit, access agreement, or limited-use contractual arrangement.

The central legal question is whether a researcher receives only permission to use a material for specified research, or also acquires ownership rights, intellectual-property rights, rights over resulting inventions, or permission to commercialise discoveries.

In India, these arrangements may engage contract law, biological-diversity legislation, patent law, privacy and data-protection rules, research ethics, and regulations governing human biological materials.

2. Meaning and essential characteristics

A genetic-material research lease generally contains the following elements:

Identifiable material: The biological sample, cell line, sequence, organism, or genetic resource is clearly described.

Limited purpose: Use is restricted to specified experiments, research questions, or approved projects.

Defined duration: The agreement specifies when access begins and ends, and whether renewal is permitted.

Restrictions on transfer: The recipient may be prohibited from transferring samples to third parties or using them in unauthorised research.

Rights over discoveries: The contract allocates ownership or licensing rights in inventions, research results, derivatives, and datasets.

Return or destruction: The recipient may have to return remaining material or destroy it after the authorised period, subject to applicable retention requirements.

Compliance obligations: The parties must comply with relevant laws, consent requirements, biosafety conditions, and institutional policies.

A contractual right to use a sample does not automatically confer ownership of the donor's genetic information, a patent over a naturally occurring gene, or the right to undertake every conceivable experiment with the sample.

3. Legal framework in India

A. Biological Diversity Act, 2002

The Biological Diversity Act, 2002 is particularly important when genetic materials are derived from biological resources occurring in India. Its purposes include biodiversity conservation, sustainable use, and fair and equitable sharing of benefits arising from the use of biological resources and associated knowledge.

IndiaCode+1

Key provisions to examine include:

Sections 3–6: Regulate specified access to biological resources and associated knowledge, transfer of research results, and intellectual-property applications, subject to the applicable statutory conditions and exemptions.

Section 7: Addresses access by persons covered by that provision, subject to the Act's requirements and exemptions.

Sections 18 and 21: Concern the functions of the National Biodiversity Authority and benefit-sharing arrangements.

Section 52A: Provides for the relevant appellate jurisdiction of the National Green Tribunal in matters specified by the Act.

The Biological Diversity (Amendment) Act, 2023, came into force in 2024. The Biological Diversity Rules, 2024, and the Access and Benefit Sharing Regulations, 2025, are also important when assessing a proposed transaction. The 2025 regulations address access to biological resources, associated knowledge, research and commercial utilisation, and benefit sharing.

National Biodiversity Authority+3

Practical implication: Calling an agreement a “lease” does not remove statutory obligations. Parties should determine whether the material falls within the legislation, which category of person is accessing it, the purpose of access, and whether approval, prior intimation, benefit sharing, or another compliance step is required.

B. Indian Contract Act, 1872

The Contract Act supplies general principles governing enforceable research agreements.

Relevant provisions include:

Section 10: Requirements for valid contracts.

Section 23: Agreements with unlawful objects or consideration are void.

Sections 73–75: Compensation for breach and related remedies.

Section 124: Defines a contract of indemnity.

Section 148: Defines bailment, which may be relevant where tangible biological samples are delivered for a limited purpose and must be returned or otherwise dealt with under the agreement.

A research agreement can restrict the recipient's use of samples, require confidentiality, allocate specified risks, and establish consequences for unauthorised transfer. However, contractual language cannot legalise conduct prohibited by statute or override mandatory research-consent requirements.

C. Patents Act, 1970

A research agreement must distinguish the right to use biological material from the right to patent an invention arising from it.

Section 3(c) excludes from patentability the mere discovery of a scientific principle or the formulation of an abstract theory, as well as the discovery of a living thing or non-living substance occurring in nature. Section 3(j) addresses plants and animals, in whole or in part, other than microorganisms, and specified biological processes.

A research licence therefore does not guarantee that a resulting gene-related discovery, biological product, or method will be patentable. Nor does it automatically give the researcher permission to use third-party patented technology.

D. Human biological samples, consent, and privacy

Human blood, tissue, cells, and genomic data require additional scrutiny.

Depending on the research, the parties may need to address:

Informed consent and the scope of consent for secondary use.

Ethics committee review and institutional research requirements.

Coding, anonymisation, re-identification risk, and data security.

Cross-border transfer and access to genomic information.

Withdrawal requests, sample destruction, and legally required retention.

Commercial use and disclosure of financially significant discoveries.

The right to possess a sample, permission to conduct research, and permission to commercialise a discovery are separate legal questions.

4. Important case laws

The following decisions provide useful principles for evaluating genetic-material leasing. The US decisions are persuasive comparative authorities, not binding Indian precedents.

1. Moore v. Regents of the University of California (1990), 51 Cal. 3d 120

Facts: John Moore's spleen was removed during treatment for leukaemia. Researchers subsequently developed a commercially valuable cell line from his tissues without adequately disclosing their financial interests and intended research uses.

Legal principle: The California Supreme Court rejected Moore's conversion claim based on a continuing ownership interest in the excised cells, but recognised that the physicians could be liable for breaching disclosure and informed-consent duties. The Court distinguished ownership of the removed tissue from duties owed by researchers and physicians.

PubMed

Relevance to research leasing: A donor's consent to medical treatment or sample collection should not be assumed to authorise every later commercial use. Agreements should clearly specify the permitted research, foreseeable commercial applications, and any applicable disclosure or consent obligations.

Important limitation: Moore does not establish a universal rule that all biological samples are unowned or that every donor lacks property rights. Its holding is jurisdiction-specific.

2. Greenberg v. Miami Children's Research Institute (2003), 264 F. Supp. 2d 1064

Facts: Families and organisations contributed tissue, samples, and research assistance to support research into Canavan disease. Researchers subsequently developed and commercialised a diagnostic test.

Legal principle: The litigation examined claims involving informed consent, fiduciary obligations, unjust enrichment, and control over donated research materials. The court rejected the donors' unjust-enrichment claim on the facts before it and did not recognise a general ownership entitlement in the research results merely because the donors had contributed materials or assistance.

Relevance to research leasing: A supplier or donor should not assume that providing genetic material automatically entitles them to royalties, co-ownership of patents, or control over every resulting discovery. Those rights should be negotiated expressly, subject to applicable law.

3. Washington University v. Catalona (2007), 490 F.3d 667

Facts: A prostate-cancer researcher sought to transfer donated biological samples from Washington University to another institution after leaving the university.

Legal principle: The Eighth Circuit upheld the university's control over the donated samples under the circumstances, including the donor documentation and the institution's role in receiving and maintaining them.

Relevance to research leasing: Custody, institutional control, and permission to transfer biological samples are important. An individual investigator may not have authority to move samples or grant a third party access merely because they collected or studied them.

Practical lesson: Agreements should identify the lawful custodian, the person authorised to approve transfers, and the circumstances in which material can be moved to another laboratory.

4. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013), 569 U.S. 576

Facts: The dispute concerned patents on BRCA1 and BRCA2 genes associated with breast and ovarian cancer.

Legal principle: The US Supreme Court held that a naturally occurring DNA segment does not become patent-eligible merely because it has been isolated. Synthetically created complementary DNA, or cDNA, was treated differently, subject to the Court's reasoning and applicable patent law.

Relevance to research leasing: A licence to access a natural gene or biological sample is not equivalent to a licence to practise a patent. Contracts should distinguish naturally occurring materials, engineered constructs, patented methods, and inventions developed during the project.

Limitation: Patent eligibility rules differ across jurisdictions. Indian patentability must be assessed under the Patents Act, 1970, rather than by directly applying the US decision.

5. Divya Pharmacy v. Union of India (2018), 2018 SCC OnLine Utt 1035

Facts: Divya Pharmacy, an Indian manufacturer of Ayurvedic medicines and nutraceutical products, challenged a demand for fair and equitable benefit sharing arising from its commercial use of biological resources.

Legal principle: The Uttarakhand High Court upheld the relevant benefit-sharing framework and recognised the statutory authority to impose benefit-sharing obligations on Indian entities engaged in commercial utilisation, in the circumstances addressed by the judgment.

abs.nls.ac.in+1

Relevance to genetic-material leasing: A contract involving Indian plant varieties, microbial resources, or other biological resources may require benefit-sharing arrangements even where the parties are Indian entities. The result depends on the applicable statutory provisions, the nature of the resource, and the transaction's purpose.

Limitation: This decision concerned commercial utilisation of biological resources, not a general rule that every academic research agreement involving DNA or tissue attracts the same payment obligation.

6. Association for Molecular Pathology v. Myriad Genetics, Inc. and the distinction between material and intellectual property

The Myriad decision is also significant when read alongside Indian patent law: access to a biological resource does not itself confer ownership of a patentable invention, and possession of material does not establish that a claimed invention satisfies the legal requirements for patent protection.

In a research lease, the parties should separately address:

Ownership of the original sample.

Ownership of newly developed cell lines or modified organisms.

Rights in genetic data and research results.

Patent applications and licensing.

Rights to publish results and commercialise products.

5. International legal framework

Three international instruments are particularly relevant.

India's biodiversity framework implements aspects of its obligations under the Convention on Biological Diversity and Nagoya Protocol. The exact rules applicable to a transaction depend on the resource, country of origin, parties, and intended utilisation.

National Biodiversity Authority+2

6. Essential clauses in a genetic-material research lease

A well-drafted agreement should cover the following matters.

1. Description and provenance

Identify each sample, accession number, species, cell line, sequence, source institution, and collection date where applicable. Record the lawful source and any restrictions attached to the material.

2. Permitted research use

Define the authorised experiments, research objectives, facilities, permitted users, and prohibited activities. Require written approval for material changes in purpose.

3. Duration and termination

Specify the access period, renewal procedure, termination triggers, and post-termination treatment of samples, derivatives, and data.

4. Fees and benefit sharing

Distinguish access fees, research funding, royalties, milestone payments, and statutory benefit-sharing obligations. Contractual payments do not automatically discharge regulatory obligations.

5. Intellectual property

Allocate rights in background IP, new inventions, improvements, derivatives, patent filings, and commercial licences. State clearly whether the provider receives royalties or other benefits.

6. Consent, ethics, and biosafety

Require appropriate donor consent, ethics approvals, containment measures, lawful data handling, and compliance with applicable institutional and regulatory requirements.

7. Derivatives and onward transfer

Define whether researchers may create derivative cell lines, modified organisms, extracts, or sequence databases, and whether third-party access requires prior written permission.

8. Liability and dispute resolution

Address unauthorised use, contamination, loss of samples, confidentiality breaches, indemnities, insurance, governing law, and dispute resolution.

7. Common legal disputes

A. Ownership of genetic material

A dispute may arise when the provider considers a sample its property but the researcher claims rights in newly created cell lines or derivatives.

Legal approach: Distinguish the original material from products developed through research. Examine the source agreement, consent documents, statutory restrictions, and the nature of the derivative.

B. Commercialisation beyond the agreed purpose

A university might provide a microbial strain for non-commercial research, but a recipient later develops a commercially valuable therapeutic product.

Legal approach: Examine the scope of the original permission, any change-of-purpose provisions, patent rights, and applicable benefit-sharing obligations. Commercialisation may require additional consent, authorisation, or contractual payments.

C. Unauthorised transfer to a third party

A researcher may transfer samples to an overseas laboratory without the provider's permission.

Legal approach: Review onward-transfer restrictions, cross-border regulatory requirements, data-protection duties, and any applicable biodiversity approvals. A contractual permission to transfer samples cannot override statutory restrictions.

D. Disputes over traditional knowledge and community benefits

Genetic resources may be associated with traditional knowledge held by indigenous or local communities.

Legal approach: Determine whether access and use trigger applicable access-and-benefit-sharing requirements, and whether monetary or non-monetary benefits are required. A commercial contract between two laboratories does not necessarily resolve the rights of affected communities.

8. Illustrative example

Suppose an Indian university provides a microbial strain to a biotechnology company for a two-year research project. The company later discovers a useful enzyme and seeks to develop a commercial product.

The legal questions include:

Was the strain obtained and transferred lawfully?

Does the Biological Diversity Act apply, and were all required regulatory steps completed?

Does the agreement authorise commercial development?

Who owns the enzyme-related invention and any associated patent rights?

Are royalties, community benefits, or regulatory benefit sharing payable?

Must the company return or destroy the original strain after termination?

May the company retain derivative strains and research data?

The answer depends on the agreement, the source and nature of the strain, the parties' legal status, and the applicable law. Merely paying a lease fee would not settle all these issues.

9. Remedies for breach

Depending on the jurisdiction and circumstances, available remedies may include:

Damages for contractual breach.

Injunctions restraining unauthorised use or transfer.

Termination of the agreement.

Return or destruction of material, where legally permissible.

Contractual indemnity and reimbursement of losses.

Regulatory directions, penalties, or other statutory consequences.

Patent-related remedies where enforceable intellectual-property rights have been infringed.

The availability of any remedy depends on the relevant statute, contract, evidence, and jurisdiction. Human biological materials and research data may also be subject to mandatory retention or other legal requirements that prevent unconditional destruction.

10. Conclusion

Leasing genetic materials for research is best understood as a limited, regulated grant of access and use, rather than an ordinary transfer of property. The principal legal challenge is coordinating contractual rights with biological-resource regulation, informed consent, intellectual property, data protection, biosafety, and equitable benefit sharing.

For Indian transactions, the Biological Diversity Act, 2002, as amended, the applicable 2024 Rules, the 2025 Access and Benefit Sharing Regulations, the Contract Act, and the Patents Act form important parts of the analysis. The decisions in Moore, Greenberg, Catalona, Myriad, and Divya Pharmacy illustrate different aspects of ownership, consent, institutional control, patentability, and benefit sharing.

The central rule is that permission to research a genetic material does not automatically confer ownership of the material, unrestricted permission to commercialise it, or exclusive rights over the resulting discoveries.

Research note: This is a general legal overview, not a substitute for advice on a specific transaction. For a proposed agreement, the decisive facts include the material's source, the identities and nationalities of the parties, whether the research is academic or commercial, and whether human samples, traditional knowledge, or cross-border transfers are involved.